Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLETLI (Adalimumab) in Non-infectious Uveitis
NCT05180526Phase 4Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Dec 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in uveitis, sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Duration of treatment failure at 24 weeks. Started Dec 2021; status: completed.
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT05180526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180526.